Key result
Heart-type fatty acid-binding protein (H-FABP) yielded a pooled sensitivity of 84% and specificity of 84% for the early diagnosis of acute myocardial infarction.
Why the study?
Does H-FABP testing accurately diagnose acute myocardial infarction in patients suspected of having AMI?
Meta-Analysis (n=3,709)
Does H-FABP testing accurately diagnose acute myocardial infarction in patients suspected of having AMI?
H-FABP does not have sufficient sensitivity or specificity to be used as a stand-alone test for the early diagnosis of acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
H-FABP lacks sufficient accuracy for standalone early AMI diagnosis; reinforces troponin-based strategies while leaving combined use unresolved.
OBJECTIVE: To determine the accuracy of heart-type fatty acid-binding protein (H-FABP) as a new and early cardiac biomarker in the early diagnosis of acute myocardial infarction (AMI). The introduction of early and safe biomarkers could lead to (a) a large reduction in unnecessary hospital referrals of patients suspected of, but not, having AMI and (b) an earlier start of treatment in patients with AMI. DESIGN: Diagnostic meta-analysis. SETTING: Hospital and pre-hospital. PATIENTS: Consecutive patients suspected of having AMI. MAIN OUTCOME MEASURES: A summary estimate for sensitivity and specificity was calculated using the bivariate random-effects approach, and covariate analysis was used to examine sources of heterogeneity between studies. RESULTS: A systematic search yielded 16 studies (3709 patients, prevalence of AMI 13-74%, male gender 49-84%, median age 64-76 years). The summary estimate was 84% (95% CI 76% to 90%) for sensitivity and 84% (95% CI 76% to 89%) for specificity. Covariate analyses revealed that the use of troponin in the reference standard for AMI (as opposed to creatine kinase or creatine kinase-myocardial band) had a significant impact on sensitivity. CONCLUSION: H-FABP does not fulfil the requirements needed for a safe and early diagnosis of AMI when used as a stand-alone test. Sound diagnostic studies examining the additional role of H-FABP combined with clinical findings and other diagnostic tests are needed to further clarify a potential future role for this cardiac biomarker.
No takes yet. Share an insight, caveat, or question.
Slot et al. (2010) conducted a meta-analysis in acute myocardial infarction (n=3,709). Heart-type fatty acid-binding protein (H-FABP) was evaluated on Sensitivity and specificity for early diagnosis of AMI (Sensitivity 84%, Specificity 84%, 95% CI 76-90 for sensitivity; 76-89 for specificity). Heart-type fatty acid-binding protein (H-FABP) yielded a pooled sensitivity of 84% and specificity of 84% for the early diagnosis of acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: